ArticlesCannabis use and risk of psychotic or affective mental health outcomes: a systematic review
Introduction
Cannabis, or marijuana, is the most commonly used illegal substance in most countries, including the UK and USA.1, 2, 3 About 20% of young people now report use at least once per week or heavy use (use on >100 occasions).4, 5 Use has increased particularly during early adolescence, when the developing brain might be especially susceptible to environmental exposures.6 Experimental studies7, 8, 9, 10 and surveys of users11, 12, 13 provide strong evidence that cannabis intoxication can produce transient, and usually mild, psychotic and affective experiences. Of greater concern are chronic symptoms that persist beyond, or occur independently of, intoxication effects.
Whether cannabis increases the incidence of established syndromes such as schizophrenia or depression is unclear, but this question is important because these disorders lead to substantial distress for individuals and their families, and to public burden from health-care costs. Randomised controlled trials (RCTs) of cannabis for medical use14 are unlikely to be helpful in addressing the question of causality because there are substantial differences between the pharmacokinetic profiles of such preparations and of cannabis used as a recreational drug. The typically short follow-up periods of such trials also substantially hinder interpretation of results.
Previous reviews in this field have not been very systematic, have examined broad psychosocial outcomes rather than mental illness, or have included cross-sectional data.15, 16, 17, 18, 19 We have systematically reviewed longitudinal studies of cannabis use and subsequent psychotic or affective mental health outcomes, and we have assessed the strength of evidence that cannabis use and these outcomes are causally related.
Section snippets
Study selection and data collection
Studies were included if they were population-based longitudinal studies, or case-control studies nested within longitudinal designs. We excluded cohorts of people with mental illness or substance-use-related problems, studies of prison populations, and RCTs of cannabis for medical use.14
Diagnostic outcomes for psychosis included schizophrenia, schizophreniform, schizoaffective, or psychotic disorders, non-affective or affective psychoses, psychosis not otherwise specified, psychotic symptoms,
Results
Searches of electronic bibliographic databases, expert advice, and searches of reference lists of included studies and other reviews yielded 4804 references. On the basis of their titles and abstracts, we judged that 175 (3Ā·6%) of these references potentially contained enough detail to be relevant. 143 of these references were excluded as not relevant when we had read the whole paper. Details of the studies that were excluded at this stage, including those that we regarded as near misses, are
Discussion
We found a consistent increase in incidence of psychosis outcomes in people who had used cannabis. There was no statistical evidence of publication bias, although this finding was based on only seven studies. The pooled analysis revealed an increase in risk of psychosis of about 40% in participants who had ever used cannabis. However, studies tended to report larger effects for more frequent use, with most studies showing a 50ā200% increase in risk for participants who used most heavily. A
References (69)
- et al.
Alcohol and drug use in UK university students
Lancet
(1996) A community survey of adverse effects of cannabis use
Drug Alcohol Depend
(1996)- et al.
Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies
Lancet
(2004) - et al.
Meta-analysis in clinical trials
Control Clin Trials
(1986) - et al.
Cannabis and schizophrenia. A longitudinal study of Swedish conscripts
Lancet
(1987) - et al.
Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction
Biol Psychiatry
(2005) - et al.
Cocaine use and other suspected risk factors for obsessiveācompulsive disorder: a prospective study with data from the epidemiologic catchment area surveys
Drug Alcohol Depend
(1993) - et al.
Longitudinal study of co-occurring psychiatric disorders and substance use
J Am Acad Child Adolesc Psychiatry
(1998) - et al.
Testing hypotheses about the relationship between cannabis use and psychosis
Drug Alcohol Depend
(2003) - et al.
Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient
Brain Res
(1993)